



Treatment Options for Relapsed or Refractory Multiple Myeloma

Thursday, May 26, 2016; 10:00 AM – 4:15 PM

Agenda

Hilton Frontenac

1335 S. Lindbergh Blvd, Frontenac, MO 63131

Time	Activity
9:30 am – 10:00 am	Registration
10:00 am – 10:15 am	Meeting Convened and Opening Remarks: <ul style="list-style-type: none"> Steven Pearson, MD, MSc, President, ICER
10:15 am – 11:30 am	Presentation of the Evidence: <ul style="list-style-type: none"> Dan Ollendorf, PhD, ICER Josh Carlson, PhD, MPH, University of Washington Rick Chapman, PhD, MS, ICER
11:30 am – 12:00 pm	Public Comments and Discussion: <i>Members of the public pre-registered to deliver oral remarks; alphabetical by last name</i>
12:00 pm – 12:30 pm	Manufacturer Comments and Discussion <i>Alphabetical by company name</i>
12:30 pm – 1:00 pm	Break for Lunch
1:00 pm – 2:30 pm	Midwest CEPAC Q&A with Clinical Experts Midwest CEPAC Deliberation and Votes: <i>ICER staff and clinical experts will be available for questions from the Council during deliberation</i>
2:30 pm – 4:00 pm	Policy Roundtable
4:00 pm – 4:15 pm	Meeting Adjourned

Meeting Participants

Midwest CEPAC Panel

Name	Organization	Disclosure
Eric Armbrrecht, PhD	St Louis University Center for Health Outcomes Research	*
Ryan Barker	Missouri Foundation for Health	*
Aaron Carroll, MD	Indiana University School of Medicine	*
Donald Casey, MD, MPH, MBA	Alvarez & Marsal Healthcare Industry Group; IPO4Health; Jefferson College of Population Health; Rush Medical College	*
Rena Conti, PhD	University of Chicago	*
Susan Feigenbaum, Ph.D.	University of Missouri, St. Louis	*
Jill Johnson, Pharm. D.	University of Arkansas for Medical Sciences	*
Mary Klix, MD	SLUCare Physician Group	*
Janice Meyer, MSN	St. Anthony's Health Care Partners	*
Rajiv Patel, MD	SSM DePaul Hospital	*
Harold Pollack, PHD	University of Chicago	*
Scott Micek, Pharm. D.	St. Louis College of Pharmacy	*
Reem Mustafa, MD	University of Missouri-Kansas City School of Medicine	*
Shumei Yun, MD, PhD	MO Department of Health and Senior Services	*

*No conflicts of interest to disclose, defined as more than \$10,000 in health care company stock or more than \$5,000 in honoraria or consultancies during the previous year from relevant health care manufacturers or insurers.

Policy Roundtable Participants

- **Yelak Biru**, North Texas Myeloma Support Group Leader, International Myeloma Foundation board of directors member
- **Deborah Collyer**, President and Founder, Patient Advocates in Research
- **Adam Kautzner, PharmD**, Vice President Drug Trend and Formulary, Express Scripts
- **Ed Pezalla, MD, MPH**, Vice President and National Medical Director for Pharmaceutical Policy and Strategy, Aetna
- **S. Vincent Rajkumar, MD**, Professor of Medicine, Hematology & Laboratory Medicine and Pathology; Chair, ECOG Myeloma Committee; Mayo Clinic
- **Ravi Vij, MD**, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia Section; Washington University School of Medicine in St. Louis

Institute for Clinical and Economic Review (ICER) Staff and Consultants

- **Josh Carlson, PhD, MPH**, Assistant Professor, University of Washington
- **Rick Chapman, PhD, MS**, Director of Health Economics
- **Sonya Khan, MPH**, Program Director
- **Dan Ollendorf, PhD**, Chief Scientific Officer
- **Steve Pearson, MD, MSc**, President
- **David Rind, MD, MSc**, Chief Medical Officer
- **Elizabeth Russo, MD**, Research Scientist
- **Mitchell Stein, MBA**, Policy and Communications Director
- **Patricia Synnott, MALD, MS**, Research Associate